Biovica International AB (publ) (STO:BIOVIC.B)
Sweden · Delayed Price · Currency is SEK 0.4390
+0.0030 (0.69%)
At close: Feb 10, 2026
Biovica International AB Revenue
Biovica International AB had revenue of 2.68M SEK in the quarter ending October 31, 2025, with 15.74% growth. This brings the company's revenue in the last twelve months to 9.89M, up 41.22% year-over-year. In the fiscal year ending April 30, 2025, Biovica International AB had annual revenue of 8.65M with 18.53% growth.
Revenue (ttm)
9.89M
Revenue Growth
+41.22%
P/S Ratio
12.96
Revenue / Employee
412.13K
Employees
24
Market Cap
128.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 8.65M | 1.35M | 18.53% |
| Apr 30, 2024 | 7.30M | 2.08M | 39.99% |
| Apr 30, 2023 | 5.21M | 113.00K | 2.22% |
| Apr 30, 2022 | 5.10M | -2.38M | -31.84% |
| Apr 30, 2021 | 7.48M | -2.20M | -22.71% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRLAB Therapeutics AB | 85.56M |
| Sprint Bioscience AB | 50.03M |
| Alligator Bioscience AB | 46.22M |
| NextCell Pharma AB | 11.06M |
| Simris Group AB (PUBL) | 2.30M |
| Karolinska Development AB | 1.74M |
| Biosergen AB | 527.00K |